AIMS: We assessed feasibility, efficacy and safety of a suture-mediated closure device, Perclose Proglide (Abbott Vascular Devices, Santa Clara, CA, USA), for closure of the femoral vein access after percutaneous MitraClip (Abbott Vascular Devices) implantation. METHODS AND RESULTS: Venous access of 80 consecutive patients undergoing percutaneous mitral valve repair using the MitraClip device was managed either by manual compression, "figure eight" suture and compression bandage for 12 hours, or by applying the Proglide device for haemostasis after the procedure (40 patients each group). Patients with Proglide closure showed complete immediate haemostasis in 92.5% (37/40) and were immobilised with a compression bandage for only four hours. In the Proglide group, one arteriovenous fistula was observed and had to be treated by vascular surgery. The overall duration of stay on an intensive care unit was significantly reduced in the Proglide group (59.4±48.9 hours vs. 84.6±59.5 hours, p<0.005). CONCLUSIONS: Using a suture-mediated closure device for the femoral vein after percutaneous MitraClip implantation is feasible and safe. This allows earlier patient mobilisation and may reduce post-interventional duration of stay on an intensive care unit.
AIMS: We assessed feasibility, efficacy and safety of a suture-mediated closure device, Perclose Proglide (Abbott Vascular Devices, Santa Clara, CA, USA), for closure of the femoral vein access after percutaneous MitraClip (Abbott Vascular Devices) implantation. METHODS AND RESULTS: Venous access of 80 consecutive patients undergoing percutaneous mitral valve repair using the MitraClip device was managed either by manual compression, "figure eight" suture and compression bandage for 12 hours, or by applying the Proglide device for haemostasis after the procedure (40 patients each group). Patients with Proglide closure showed complete immediate haemostasis in 92.5% (37/40) and were immobilised with a compression bandage for only four hours. In the Proglide group, one arteriovenous fistula was observed and had to be treated by vascular surgery. The overall duration of stay on an intensive care unit was significantly reduced in the Proglide group (59.4±48.9 hours vs. 84.6±59.5 hours, p<0.005). CONCLUSIONS: Using a suture-mediated closure device for the femoral vein after percutaneous MitraClip implantation is feasible and safe. This allows earlier patient mobilisation and may reduce post-interventional duration of stay on an intensive care unit.
Authors: Moghniuddin Mohammed; Rigoberto Ramirez; Daniel A Steinhaus; Omair K Yousuf; Michael J Giocondo; Brian M Ramza; Alan P Wimmer; Sanjaya K Gupta Journal: J Interv Card Electrophysiol Date: 2021-04-02 Impact factor: 1.759
Authors: Nicolas A Geis; Sven T Pleger; Raffi Bekeredjian; Emmanuel Chorianopoulos; Michael M Kreusser; Lutz Frankenstein; Arjang Ruhparwar; Hugo A Katus; Philip W J Raake Journal: ESC Heart Fail Date: 2018-07-30
Authors: Livia Gheorghe; Alfonso Ielasi; Benno J W M Rensing; Frank D Eefting; Leo Timmers; Azeem Latib; Martin J Swaans Journal: Front Cardiovasc Med Date: 2019-10-18
Authors: Katharina Schnitzler; Michaela Hell; Martin Geyer; Felix Kreidel; Thomas Münzel; Ralph Stephan von Bardeleben Journal: Curr Cardiol Rep Date: 2021-08-13 Impact factor: 2.931
Authors: Nicolas A Geis; Anna Göbbel; Michael M Kreusser; Tobias Täger; Hugo A Katus; Norbert Frey; Philipp Schlegel; Philip W Raake Journal: Life (Basel) Date: 2022-02-25